Safety, Tolerance, and Pharmacokinetics of Xanomeline Tartrate: A Novel Muscarinic M1 Agonist in Healthy Elderly Subjects

  • R. A. Lucas
  • J. Heaton
  • G. V. Carter
  • J. H. Satterwhite
Part of the Advances in Behavioral Biology book series (ABBI, volume 44)

Abstract

Xanomeline (LY246708/NNC-11-0232) was previously shown to be well tolerated in healthy young subjects at single doses up to 75 mg, and in a 7-day multiple dose study at doses of 75 mg bid. As the compound will predominantly be used therapeutically in an older patient population, this study was designed to establish the tolerability and safety in healthy elderly subjects prior to Alzheimer patient studies. Many drugs have an increased liability to affect homeostatic mechanisms (e.g. blood pressure) and the elderly are often less tolerant of CNS acting agents. Decrease in oral absorption and rates of clearance in the elderly may differ greatly, factors considered highly possible for xanomeline tartrate.

Keywords

Paroxysmal Atrial Fibrillation Healthy Elderly Subject Postural Dizziness Musculoskeletal Discomfort Stuffy Nose 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • R. A. Lucas
    • 1
  • J. Heaton
    • 1
  • G. V. Carter
    • 1
  • J. H. Satterwhite
    • 2
  1. 1.Erl Wood Manor WindleshamLilly Research CentreSurreyUSA
  2. 2.Lilly Laboratory for Clinical ResearchIndianapolisUSA

Personalised recommendations